medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 3

<< Back Next >>

Rev Invest Clin 2005; 57 (3)

Treatment of acute promyelocytic leukemia: A single institution experience

Ruiz-Argüelles GJ, Morales-Toquero A, Gómez-Rangel JD, Lopez-Martinez B, Ruiz-Delgado GJ, Reyes-Núñez V

Language: English
References: 31
Page: 415-419
PDF size: 56.48 Kb.


ABSTRACT

The results of the treatment of 14 patients with promyelocytic leukemia (PML) treated with all trans-retinoic acid (ATRA), combined chemotherapy (CT) and prophylactic prednisone are reported; the median age was 30 years (range 7 - 49). A complete remission (CR) was obtained in 13 / 14 patients (93%). All patients were given ATRA fully as outpatients; the CR was achieved after the administration of ATRA in five patients, whereas in the remaining eight, CT was required to achieve it. There were no instances of the ATRA syndrome. One patient relapsed with a PML/RAR-a negative PML 575 days after achieving the CR, failed to respond again to ATRA and died. The median overall (OS) and disease free survival (DFS) has not been reached, being above 4,000 days, whereas the 12-month DFS was 93%, the three and five years DFS being 85%. The treatment employed differs from others in: Oral prednisone is used prophylactically, ATRA is given on an outpatient basis and adriamycin is used instead of other anthracyclines. The results are similar to those obtained in other centers worldwide and it is possible that the prophylactic administration of prednisone precluded the development of the full-blown ATRA syndrome in this group of patients.


REFERENCES

  1. Kakizuka A, Miller WH, Umesono K, Warrel RP, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM. Chromosomal translocation t (15;17) in acute promyelocytic leukemia fuses RAR-alpha with a novel putative transcription factor PML. Cell 1991; 66: 663.

  2. De Thé, Lavau C, Marchio A, Chomienne C, Lanotte M, Degos L, Dejean A. The PML / RAR-alpha fusion mRNA generated by the t (15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675.

  3. Turhan AG, Lemoine FM, Debert C, Bonnet ML, Baillou C, Picard F, Macintyre EA, Varet B. Highly purified primitive hematopoietic stem cells are PML/RAR-alpha negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 1995; 85: 2154-61.

  4. Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Argüelles A. Continued complete remission after a PML/RAR-a positive autograft in acute promyelocytic leukemia. Eur J Haematol 1996; 56: 186-7.

  5. Miller WJR, Kakizuka A, Frankel SR. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694.

  6. Ruiz-Argüelles GJ, Garcés-Eisele J, Ruiz-Argüelles A. Molecular follow-up of patients with promyelocytic leukaemia treated with all trans-retinoic acid. Clin Lab Haematol 1998; 20: 173-6.

  7. Miller WH, Levine K, deBlasio A, Frankel SR, Dmitrovsky E, Warrel RP Jr. Detection of minimal residual disease un acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML 7 RAR-alpha fusion mRNA. Blood 1993; 82: 1689-94.

  8. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Cocco F, Grignani F, Pelicci PG. Acute promyelocytic leukemia: From genetics to treatment. Blood 1994; 83: 10-25.

  9. Ruiz-Argüelles GJ, Ruiz-Argüelles A, Pérez-Romano B, Marín-López A, Larregina-Díez A, Apreza-Molina MG. Filgrastim-mobilized peripheral blood stem cells can be stored at 4 degrees and used in autografts to rescue high-dose chemotherapy. Am J Hematol 1995; 48:100-3.

  10. Ruiz-Argüelles GJ.: Promyelocytic leukemia in Mexican mestizos. Blood 1997; 89: 348-9.

  11. Ruiz-Argüelles GJ, Gómez-Almaguer D, Delgado-Lamas JL, Mejía Domínguez AM, Gil-Rondero C, Almaguer-Gaona C, Apreza-Molina MG. High frequency of acute promyelocyitic leukemia in Mexican Mestizos. A multicenter study. Brit J Haematol 1998; 102(Suppl. 1): 37.

  12. Rubio-Borja ME, Ovilla-Martínez R, Labardini J, Gómez-Almaguer D, Ruiz-Argüelles GJ, Gómez-Morales E, Borbolla R. All-trans retinoic acid (ATRA) for acute promyelocytic leukemia (APL): Toxicity and survival in de novo patients. Blood 1994; 84(Suppl. 1): 147a.

  13. Ruiz-Argüelles GJ, Lobato-Mendizábal E, Delgado-Lamas JL, Gómez-Almaguer D. All trans-retinoic acid decreases early mortality in patients with promyelocytic leukemia and can be given entirely on an outpatient basis. Am J Hematol 1999; 62: 139-43.

  14. Ruiz-Argüelles GJ, McArthur J. Leucemias agudas. In: Ruiz-Argüelles GJ (editor): Fundamentos de Hematología. 3rd. Edition. México: Editorial Médica Panamericana; 2003, pp. 180-97.

  15. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Ann Biol Clin 1992; 50: 735-43.

  16. Ruiz-Argüelles A, Duque RE, Orfao A. Report of the first Latin American consensus conference for flow cytometric immunophenotyping of leukemia. Cytometry (Communications in Clinical Cytometry) 1998; 34: 39-42.

  17. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, LeCoco F, Diverio D, Pagliani EM, Lanzi EM, Mandelli F, Masera G, Barbui T, Pellici PG. Molecular monitoring of the myl/retinoic acid receptor alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-7.

  18. Ruiz-Argüelles GJ, Apreza-Molina MG, Alemán-Hoey DD, Gómez-Almaguer D, Marín-López A, Mercado-Díaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: A multicentre study. Eur J Haematol 1995; 54: 18-20.

  19. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Ruiz-Argüelles A, Pérez-Romano B, Rivadeneyra L. Results of an autologous non-cryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: A single institution, 10-year experience. Acta Haematol 2003; 110: 179-83.

  20. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-63.

  21. Douer D, Santillana S, Ramezani L, Samanez C, Slovak ML, Lee MS, Watkins K, Williams T, Vallejos C. Acute promyelocytic leukemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARa fusion gene. Brit J Haematol 2003; 122, 563-70.

  22. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Reyes-Núñez V. PML/RARa (+) hypergranular acute promyelocytic leukemia (M3) developing into an M3 acute myelocytic leukemia without PML/RARa. Acta Haematol 2000; 104: 124-7.

  23. Otero JC, Santillana S, Fereyros G. High frequency of acute promyelocytic leukemia among latinos with acute myeloid leukemia (Letter). Blood 1996; 88: 377.

  24. Almaguer-Gaona C, Cantú-Rodríguez OG, Hernández-Garza NE, Gómez-Almaguer D. Leucemia aguda. Observaciones epidemiológicas en el Hospital Universitario de la Universidad Autónoma de Nuevo León. Medicin Univ 1998; 1: 15.17.

  25. Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia 1997; 11: 1661-4.

  26. Ruiz-Argüelles GJ, Gómez-Almaguer D, Delgado-Lamas JL, Gil-Rondero C, Almaguer-Gaona C, Apreza-Molina MG. High frequency of acute promyelocytic leukemia in Mexican mestizos. A multicenter study. Blood 1997; 90(Suppl. 1): 233b (Abstract).

  27. Piedras J, López-Karpovitch X, Cárdenas MR. Cellular immunophenotypes in 97 adults with acute leukemia. Rev Invest Clín Méx 1997; 49: 457-64.

  28. Ruiz-Argüelles GJ, Garcé-Eisele J, Reyes-Núñez V, Gómez-Rangel JD, Ruiz-Delgado GJ. More on geographic hematology: the breakpoint cluster regions of the PML/RAR alpha fusion gene in Mexican Mestizo patients with promyelocytic leukemia are different from those in Caucasians. Leuk Lymphoma 2004; 45: 1365-8.

  29. Tallman MS. Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 2004; 41: 27-32.

  30. Sanz MA, Lo Cocco F, Martin G, Avissati G, Rayón C, Barbui T, Díaz-Mediavilla J, Floritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, González M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-53.

  31. Warrel RP, Jr. Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 1996; 47: 555-65.




2020     |     www.medigraphic.com